Clinical Trial Update: High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx) [Phase 2]

View source ↗

Summary

Phase 2 trial update for high-risk ER+/HER2- early breast cancer evaluating palbociclib plus endocrine therapy (HIPEx).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN